Published: 23 July 2020

Safety Information


Medsafe emphasises that patients should NOT stop using any medicine or medical device subject to a monitoring communication. If you have any concerns with a medicine or medical device you are using, please contact your healthcare professional. A monitoring communication does not mean that the medicine or medical device causes an adverse event.

M² Logo Yes! Cassette Pregnancy Test Kit (also known as Smiths BioMed Rapid Pregnancy Test Kit) – Reports of false positives presenting as faint lines and inconclusive results


24 July 2020

Medsafe has received several reports from clinicians, DHBs, clinics and community providers about the Yes! Cassette Pregnancy Test Kits (also known as the Smith BioMed Rapid Pregnancy Test), shown in Figure 1 below. The reports describe false positive test results and inconclusive results. These present as faint lines.

Medsafe is asking health care professionals to report any issues experienced with these test kits, to assist with our decision making.

Products affected
Additional information
Regulator actions

Products affected

Product name Sponsor
Yes! Cassette Pregnancy Test Kit

All Batch numbers:
Smith BioMed New Zealand

Additional information

These tests are used as an early detection test for pregnancy. The test is accurate if used 7 days after the next period is due. Hormone levels in women vary and some women may not have detectable levels of hormone on the first day they test for it.

Yes! Cassette Pregnancy Test Kit information leaflet

PHARMAC funds this pregnancy test kit. However, on the Pharmaceutical Schedule, the test kit is called the Smith BioMed Rapid Pregnancy Test (2544873).

Figure 1: Image of the test kit box (a) and test kit (b)

YES Pregnancy Test Kit YES Pregnancy Test Kit
(a)  (b)

Regulator actions

Medsafe will continue to monitor this issue and will produce updated advice for health care professionals as necessary.


Health care professionals are encouraged to report issues with this product to Medsafe. Please include in your report:

  • a description of the issue
  • the total number of affected tests
  • batch numbers
  • any other relevant information.

If you have questions about this monitoring communication, please email:

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /